HOME › Research Insight › Aptamers Technology & Market – Forecasts (2013-2018)
Aptamers Technology & Market – Forecasts (2013-2018)
Aptamers Market generated through Systematic Evolution of Ligands by EXponential enrichment (SELEX) have rapidly emerged as a novel.
Aptamers are relatively short (12-30 base) ssDNA or RNA oligonucleotides (or peptides) that were first described in 1980s, representing a promising class of therapeutics. Regardless of rising competition from various small molecules and technologies, the aptamer manufacturers/providers foresee an extraordinary growth. Aptamers are considered as an effective alternative to antibodies in many application areas.
Though antibodies and aptamers possess binding affinities in low nanomolar to picomolar range, some properties of aptamers make them attractive therapeutic agents compared with antibodies. The most important being the non-immunogenic property, and the others include their small size and ease of production. Yet another advantage of aptamers for use in clincial applications is that the nucleic acids can greatly sustain chemical modifications appropriate to optimize their in vivo stability and persistence in physiological conditions, while retaining their structure and function, thus enhancing their therapeutic potential.
The aptamers have been preferred against a broad range of targets such as proteins, phospholipids, sugars, nucleic acids and whole cells and they are demonstrated clinically as inhibitors with immense potential as targeting ligands for treating or diagnosing cancer, HIV, and other diseases.
Aptamers Market has a wide range of applications including therapeutics, diagnostics, research, biomarker discovery, drug discovery, drug delivery, flow cytometry, western blotting and as biosensors. Of the aforementioned applications, research, biomarker discovery and drug discovery areas are expected to have a significant market growth in next 2-3 years.
Macugen (pegaptanib) is the first aptamer based drug approved for use in humans to treat age-related macular degeneration (AMD), targeting vascular endothelial growth factor (VEGF). So far, there are around ten RNA and DNA-aptamers entered in to the clinical trials pipeline for treating a number of indications such as Acute myeloid leukaemia (AML), Percutaneous coronary intervention, Thrombotic microangiopathies, carotid artery disease, Age-related macular degeneration, Multiple myeloma, non-Hodgkin’s lymphoma, Type II diabetes, and diabetic nephropathy.
With respect to the market share based on aptamer types, nucleic acid aptamers would have a greater market than the peptide aptamers. The adoption potential and the market with respect to geographical regions, the growth would be significant in North America followed by Asia Pacific.
Owing to the promising horizons in the therapeutics, diagnostics and other application sectors, the global market for aptamers with respect to therapeutics and diagnostics applications would be similar to the current antibody market for the mentioned applications.
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252